Form 4: Inovio Pharmaceuticals Director, David B. Weiner, Reports Stock Unit Vesting
SEC Form 4
Director David B. Weiner reports the vesting of restricted stock units into Inovio Pharmaceuticals common stock.
Summary
- On May 21, 2025, David B. Weiner, a director of Inovio Pharmaceuticals, reported the vesting of 2,167 restricted stock units.
- These units converted into 2,167 shares of common stock.
- Following the transaction, Weiner directly owns 86,620 shares of Inovio Pharmaceuticals.
Sentiment
Score: 5
Explanation: This is a neutral reporting of a routine transaction (stock unit vesting) by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.
Stakeholder Impact
- The vesting of stock units could have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of earliest transaction: vesting of restricted stock units and signature date. |
Keywords
Inovio Pharmaceuticals, Director, David B. Weiner, Stock Units, Vesting, Common Stock, Ownership, INO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.